Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > News

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Jun 29, 2020 10:50am

96 Views

Post# 31202803

RE:RE:News

The 5 bad sites must have really messed something up.....

The pre-randomization reduction in TGs across all subjects in TRILOGY 1 was about 20%, with 25% of all subjects experiencing a reduction equal to or greater than 38%. The median Pre-Randomization TG Normalization reached 30% or more in 12 out of 54 sites (or in 22% of all randomizing sites), in all, much greater than the 10% variation that would have been expected based on physiological variability.

lscfa wrote: I wish they had given some theories as to why there was an unusual TG normalization prior to start of trial. Did patients change their eating/exercise habits between the time they were told they qualify for the trial and when the trial started?

lscfa wrote: https://www.acastipharma.com/en/investors/news-events/press-releases/detail/183/acasti-pharma-provides-fiscal-2020-year-end-business-update